Publications

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O’Connor CM.
JACC Heart Fail. 2018;6:96-104. doi: 10.1016/j.jchf.2017.08.013.

Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
Pieske B, Patel MJ, Westerhout CM, Anstrom KJ, Butler J, Ezekowitz J, Hernandez AF, Koglin J, Lam CSP, Ponikowski P, Roessig L, Voors AA, O’Connor CM, Armstrong PW; VICTORIA Study Group. 
Eur J Heart Fail. 2019;21:1596-1604. doi: 10.1002/ejhf.1664.

Comparing The Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial.
Butler J, Anstrom KJ, Armstrong PW; VICTORIA Study Group. 
Circulation. 2020; 142: 717-719. doi: 10.1161/CIRCULATIONAHA.120.047086.

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors, AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM; VICTORIA Study Group. 
N Engl J Med. 2020;382: 1883-1893. doi: 10.1056/NEJMoa1915928.

Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA, O’Connor CM, Troughton RW, Alemayehu WG, Westerhout CM, Voors AA, Butler J, Lam CSP, Ponikowski P, Emdin M, Patel MJ, Pieske B, Roessig L, Hernandez AF, Armstrong PW.
JACC Heart Fail. 2020. doi: 10.1016/j.jchf.2020.08.008.

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
Lam CSP, Giczewska A, Carolyn S. P. Lam, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O’Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW; VICTORIA Study Group. 
JAMA Cardiol. 2020. doi:10.1001/jamacardio.2020.6455.

Renal Function and the Effects of Vericiguat in Patients with Worsening Heart Failure with Reduced Ejection Fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF) Trial. 
Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, Ezekowitz JA, Butler J, O’Connor CM, Koglin J, Lam CSP, Pieske B, Roessig L, Ponikowski P, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2221.

Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
Mentz RJ, Mulder H, Mosterd A, Sweitzer NK, Senni M, Butler J, Ezekowitz JA, Lam CSP, Pieske B, Ponikowski P, Voors AA, Anstrom KJ, Armstrong PW, O’connor CM, Hernandez AF; VICTORIA Study Group.
J Card Fail. 2021. doi: 10.1016/j.cardfail.2021.05.016.

Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial.
Ponikowski P, Alemayehu W, Oto A, Bahit MC, Noori E, Patel MJ, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Roessig L, Voors AA, Westerhout C, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2285.

Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.
Ezekowitz J, Mentz RJ, Westerhout CM, Sweitzer NK, Givertz MM, Piña IL, O’Connor CM, Greene SJ, McMullan C, Roessig L, Hernandez AF, Armstrong PW.
Circ Heart Fail. 2021. doi: 10.1161/CIRCHEARTFAILURE.120.008242.

Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).
Ezekowitz JA, Zheng Y, Cohen-Solal A, Melenovský V, Escobedo J, Butler J, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Voors AA, deFilippi C, Westerhout CM, McMullan C, Roessig L, Armstrong PW; VICTORIA Study Group.
Circulation. 2021. doi: 10.1161/CIRCULATIONAHA.121.056797.

Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW;VICTORIA Study Group.
J Am Heart Assoc. 2021. doi: 10.1161/JAHA.121.021094.

Vericiguat in Patients with Coronary Artery Disease and Heart Failure with Reduced Ejection Fraction.
Saldarriaga C, Atar D, Stebbins A, Lewis BS, Zainal Abidin I, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Eur J Heart Fail. 2022. doi: 10.1002/ejhf.2468.

Medical Therapy During Hospitalization for Heart Failure with Reduced Ejection Fraction: The VICTORIA Registry.
Greene SJ, Ezekowitz JA, Anstrom KJ, Demyanenko V, Givertz MM, Piña IL, O’Connor CM, Koglin J, Roessig L, Hernandez AF, Armstrong PW, Mentz RJ. Group. J Card Fail. 2022. doi: 10.1016/j.cardfail.2022.02.011.

Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial.
Butler J, Stebbins A, Melenovský V, Sweitzer NK, Cowie MR, Stehlik J, Khan MS, Blaustein RO, Ezekowitz JA, Hernandez AF, Lam CSP, Nkulikiyinka R, O’Connor CM, Pieske BM, Ponikowski P, Spertus JA, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Circ Heart Fail. 2022. doi: 10.1161/CIRCHEARTFAILURE.121.009337.

Efficacy and Safety of Vericiguat in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/Valsartan: Insights from the VICTORIA Trial.
Senni M, Alemayehu WG, Sim D, Edelmann F, Butler J, Ezekowitz J, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Westerhout CM, McMullan C, Armstrong PW; VICTORIA Study Group. Eur J Heart Fail. 2022. doi: 10.1002/ejhf.2608.

Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.
Armstrong PW, Zheng Y, Troughton RW, Lund LH, J Zhang, Lam CSP, Westerhout CM, Blaustein RO, Butler J, Hernandez AF, Roessig L, O’Connor CM, Voors AA, Ezekowitz J; VICTORIA Study Group.
J Am Coll Cardiol HF. 2022. DOI: 10.1016/j.jchf.2022.04.015.

Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: the VICTORIA Echocardiographic Substudy.
Pieske B, Pieske-Kraigher E, Lam CSP, Melenovský V, Sliwa K, Lopatin Y, Arango JL, Bahit MC, O’Connor CM, Patel MJ, Roessig L, Morris DA, Kropf M, Westerhout CM, Zheng Y, Armstrong PW; VICTORIA Study Group.
Eur J Heart Fail. 2023 Mar 30. doi: 10.1002/ejhf.2836.

Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy.
Defilippi CR, Alemayehu WG, Voors AA, Kaye D, Blaustein RO, Butler J, Ezekowitz JA, Hernandez AF, Lam CSP, Roessig L, Seliger S, Shah P, Westerhout CM, Armstrong PW, O’Connor CM; VICTORIA Study Group.
J Card Fail. 2023 Apr;29:448-458. doi: 10.1016/j.cardfail.2022.12.013. 

Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA.
Butler J, Zheng Y, Khan MS, Bonderman D, Lund LH, deFilippi CR, Blaustein RO, Ezekowitz JA, Freitas C, Hernandez AF, O’Connor CM, Voors AA, Westerhout CM, Lam CSP, Armstrong PW; VICTORIA Study Group.
JACC Heart Fail. 2023 May;11:583-592. doi: 10.1016/j.jchf.2022.12.014.


Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial
Felker GM, North R, Mulder H, Jones WS, Anstrom KJ, Patel MJ, Butler J, Ezekowitz JA, Lam CSP, O’Connor CM, Roessig L, Hernandez AF, Armstrong PW; VICTORIA Study Group.
J Card Fail. 2023 Jun:S1071-9164(23)00204-X. doi: 10.1016/j.cardfail.2023.04.015.

Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial
Ezekowitz JA, McMullan CJ, Westerhout CM, Piña IL, Lopez-Sendon J, Anstrom KJ, Hernandez AF, Lam CSP, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Voors AA, Koglin J, Armstrong PW, Butler J; VICTORIA Study Group.
Circ Heart Fail. 2023 Jul:e010599. doi: 10.1161/CIRCHEARTFAILURE.123.010599.

Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
Armstrong PW, Zheng Y, Lund LH, Butler J, Troughton RW, Emdin M, Lam CSP, Ponikowski P, Blaustein RO, O’Connor CM, Roessig L, Voors AA, Ezekowitz JA, Westerhout CM; VICTORIA Study Group.
Circ Heart Fail. 2023 Jul 28:e010661. doi: 10.1161/CIRCHEARTFAILURE.123.010661.

Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial
Lam CSP, Piña IL, Zheng Y, Bonderman D, Pouleur AC, Saldarriaga C, Pieske B, Blaustein RO, Nkulikiyinka R, Westerhout CM, Armstrong PW; VICTORIA Study Group.
JACC Heart Fail. 2023 Sep;11:1246-1257. doi: 10.1016/j.jchf.2023.06.020.

Relationship between baseline electrocardiographic measurements and outcomes in patients with high-risk heart failure: insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial
Yogasundaram H, Zheng Y, Ly E, Ezekowitz J, Ponikowski P, Lam CSP, O’Connor C, Blaustein RO, Roessig L, Temple T, Westerhout CM, Armstrong PW, Sandhu RK; VICTORIA Study Group.
Eur J Heart Fail. 2023 Sep 1. doi: 10.1002/ejhf.3021. 

Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial
Chew DS, Li Y, Bigelow R, Cowper PA, Anstrom KJ, Daniels MR, Davidson-Ray L, Hernandez AF, O’Connor CM, Armstrong PW, Mark DB; VICTORIA Study Group.
Circulation. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602. 

Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
Mentz RJ, Stebbins A, Butler J, Chiang CE, Ezekowitz JA, Hernandez AF, Hilkert R, Lam CSP, McDonald K, O’Connor CM, Pieske B, Ponikowski P, Roessig L, Sweitzer NK, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group.
Jacc Heart Fail. 2024 Jan 22. doi: 10.1161/CIRCULATIONAHA.122.063602.